Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
A phase I study demonstrated feasibility of the WEE1 inhibitor adavosertib in combination with gemcitabine and radiotherapy as first line therapy. Overall survival (27.1 months) was better than historical controls. Progression to phase II planned.
AZD1775 in combination with gemcitabine and radiation therapy was well tolerated at a dose that produced target engagement in a surrogate tissue. The overall survival is substantially higher than prior results combining gemcitabine with radiation therapy and warrants additional investigation.